Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the Biophysical Society 2022 Annual Meeting
February 15, 2022 08:00 ET
|
Cue Biopharma, Inc.
Presentation provides mechanistic insights and progress update on collaboration with the laboratory of Michael Dustin at the University of Oxford to study the role of IL-2 in the T cell immunological...
Cue Biopharma Reports Two Objective Responses (1 cPR and 1uPR) in First Interim Update from Dose Escalation Portion of Ongoing Phase 1 Combination Study of CUE-101 and KEYTRUDA® in First Line Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer
January 26, 2022 16:01 ET
|
Cue Biopharma, Inc.
Early data in the combination study of CUE-101 and KEYTRUDA® (pembrolizumab) supports synergistic activity; of four patients treated in dose escalation in the 2mg/kg and RP2D 4mg/kg cohorts, two have...
Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials
January 20, 2022 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma and LG Chem Life Sciences Announce Development Milestone in Immuno-STAT Biologics Collaboration for CUE-102
January 05, 2022 08:00 ET
|
Cue Biopharma, Inc.
Selective activation and expansion of Wilms’ Tumor 1 (WT1)-specific cytotoxic CD8+ T cells in preclinical models supports the potential for clinical activity treating WT1-expressing cancersFurther...
Cue Biopharma Announces Appointment of Patricia Nasshorn as Chief Business Officer
December 15, 2021 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
Cue Biopharma to Present at JMP Securities Hematology and Oncology Summit
December 06, 2021 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma to Present at the Piper Sandler 33rd Annual Healthcare Conference
November 22, 2021 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma Presents Updated Data from Lead Program CUE-101 for the Treatment of Recurrent/Metastatic HPV+ Head and Neck Cancer and Additional Pipeline Progress at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
November 12, 2021 08:00 ET
|
Cue Biopharma, Inc.
Monotherapy data further enhances confidence in CUE-101 potential as single agent therapeutic in the refractory/metastatic human papillomavirus positive head and neck squamous cell carcinoma (HPV+...
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November
November 10, 2021 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma Announces Publication in The Journal of Clinical Investigation Highlighting Immuno-STAT Biologics for the Treatment of Chronic Infectious Diseases
October 21, 2021 12:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...